Clinical trials · Pennsylvania
Ulcerative Colitis clinical trials in Pennsylvania
We’re tracking 24 recruiting ulcerative colitis studies with a site in Pennsylvania — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Philadelphia, PennsylvaniaAges 2–17 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Hershey, PennsylvaniaAges 16–80 - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Harrisburg, PennsylvaniaAges 12 years+ - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Philadelphia, PennsylvaniaAges 2–19 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Hershey, PennsylvaniaAges 2–17 - NCT06867094RecruitingPhase 2
Study of SAR441566 for Ulcerative Colitis
This trial tests a new medicine called SAR441566 for people with moderate-to-severe ulcerative colitis (UC). It may help reduce symptoms like bleeding and diarrhea if other treatments haven't worked well enough.
Uniontown, PennsylvaniaAges 18–75 - NCT06975722RecruitingPhase 2
Study of SAR442970 for Ulcerative Colitis
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
Harrisburg, PennsylvaniaAges 18–75 - NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Wexford, PennsylvaniaAges 18–65 - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
Pittsburgh, PennsylvaniaAges 18–85 - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Uniontown, PennsylvaniaAges 16–80 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Hershey, PennsylvaniaAges 2–17 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Pittsburgh, PennsylvaniaAges 2 years+ - NCT06405087RecruitingPhase 3
Long-term study of vedolizumab for children with IBD
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Hershey, PennsylvaniaAges 2–17 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Philadelphia, PennsylvaniaAges 18–70 - NCT06424769Enrolling by invitation
Managing Inflammatory Bowel Disease with Text Message Surveys
This study aims to improve care and reduce health gaps for people with inflammatory bowel disease using text-message surveys to track symptoms and guide better disease management.
Philadelphia, PennsylvaniaAges 13 years+ - NCT06560021Enrolling by invitation
Random biopsies in inflammatory bowel disease surveillance
This trial looks at whether taking random biopsies during a routine colonoscopy is helpful for people with inflammatory bowel disease (IBD) who are at risk for colon cancer. It aims to understand if random biopsies can detect early signs of cancer or pre-cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04243525Recruiting
Inflammatory bowel disease patient research registry
This study is a research registry that collects information from adults receiving care for inflammatory bowel disease at UPMC. It may help researchers better understand bowel disease and improve future treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06571669Recruiting
Nerve stimulation device for ulcerative colitis
This trial tests a new medical device called BOOM-IBD2 that uses gentle nerve stimulation to treat ulcerative colitis. It's for people who have not had UC surgery and do not have certain infections or other implanted devices.
Philadelphia, PennsylvaniaAges 18–85 - NCT06587828Recruiting
Looking at immune cells in people with autoimmune disease
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
Harrisburg, PennsylvaniaAges 18 years+ - NCT07198113Recruiting
Comparing newer treatments for pediatric inflammatory bowel disease
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
Pittsburgh, PennsylvaniaAges 1–18 - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02636517Enrolling by invitationPhase 1
Fecal microbiome transplant for repeat C. difficile infection
This Phase 1 study tests whether transferring healthy gut bacteria (a fecal microbiome transplant) can help children with repeated or moderate-to-severe C. difficile infection. It focuses on changing gut bacteria to reduce ongoing infection and symptoms.
Philadelphia, PennsylvaniaAges 3–21 - NCT02791854Enrolling by invitation
Improving Care for Adults With Crohn’s or Ulcerative Colitis
This trial looks at ways to improve care for adults living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. You may be invited if your clinic is part of an inflammatory bowel disease care network called IBD Qorus.
Hershey, PennsylvaniaAges 18–99
Ulcerative Colitis trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- Allegheny Health Network · 4 studies
- University of Pennsylvania · 4 studies
- University of Pittsburgh Medical Center · 4 studies
- Children's Hospital of Philadelphia · 3 studies
- Penn State Milton S Hershey Medical Center · 3 studies
- Frontier Clinical Research · 2 studies
- Susquehanna Research Group · 2 studies
- Thomas Jefferson University Hospital · 2 studies
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ulcerative Colitis trials in other states
Common questions
- Are there ulcerative colitis clinical trials in Pennsylvania?
- Yes. We're currently tracking 24 recruiting ulcerative colitis studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.